ImmunID Information

ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provides doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID’s flagship product, ImmunTraCkeR®, evaluates the patient’s immune status based on the T lymphocyte diversity, from a simple liquid biopsy. Through its PredictID clinical programs, ImmunID is establishing ImmunTraCkeR® as the immune companion diagnostic assay for immune checkpoint inhibitors and other cancer immunotherapies. ImmunID also collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. In addition, through its CLIA services, ImmunID provides its laboratory developed test ImmunTraCkeR® Dx to American doctors to evaluate their patient’s immune status. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited, CLIA-certified laboratory in the MINATEC high-tech campus in Grenoble, France. www.immunid.com - Follow ImmunID on Twitter: @ImmunID